This post has been archived and contains information that may be out of date.
Despite the COVID-19 pandemic, the Centers for Medicare & Medicaid Services (CMS) is moving forward with its survey of hospitals that participate in the 340B Drug Pricing Program in order to collect actual acquisition costs for specified covered outpatient drugs (SCODs). All 340B hospitals must submit acquisition cost data during the survey response period that runs from April 24 to May 15.
340B hospitals will be asked to provide information on the average acquisition costs for SCODs bought by hospitals during the fourth quarter of 2018 and the first quarter of 2019. The survey asks for the net acquisition costs for each SCOD acquired through the 340B program. The 340B drug acquisition cost should be reported regardless of whether the drug was dispensed or whether the drug was dispensed in multiple settings during the specified time period. Instructions, documents, and how to submit the completed survey can be found here.
